Patents by Inventor Richard J. Bertz

Richard J. Bertz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate
    Publication number: 20100261731
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Application
    Filed: April 13, 2009
    Publication date: October 14, 2010
    Applicant: Abbott Laboratories
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
    Patent number: 7547678
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: June 16, 2009
    Assignee: Abbott Laboratories
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an ugtiai substrate
    Publication number: 20080138315
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Application
    Filed: January 15, 2008
    Publication date: June 12, 2008
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
    Patent number: 7320961
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: January 22, 2008
    Assignee: Abbott Laboratories
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
    Publication number: 20040242509
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Application
    Filed: August 3, 2004
    Publication date: December 2, 2004
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
    Publication number: 20040192624
    Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
    Type: Application
    Filed: March 24, 2003
    Publication date: September 30, 2004
    Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
  • Method for improving pharmacokinetics
    Patent number: 6703403
    Abstract: A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: March 9, 2004
    Assignee: Abbott Laboratories
    Inventors: Daniel W. Norbeck, Dale J. Kempf, John M. Leonard, Richard J. Bertz
  • Method for improving pharmacokinetics
    Publication number: 20020039998
    Abstract: A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Type: Application
    Filed: September 20, 2001
    Publication date: April 4, 2002
    Inventors: Daniel W. Norbeck, Dale J. Kempf, John M. Leonard, Richard J. Bertz
  • Method for improving pharmacokinetics
    Patent number: 6037157
    Abstract: A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Type: Grant
    Filed: June 26, 1996
    Date of Patent: March 14, 2000
    Assignee: Abbott Laboratories
    Inventors: Daniel W. Norbeck, Dale J. Kempf, John M. Leonard, Richard J. Bertz